Ajai Chari, MD

Ajai Chari, MD, discusses treatment navigation in relapsed/refractory multiple myeloma in the era of CAR T-cell therapies and bispecific antibodies.

Ajai Chari, MD, discusses frontline treatment and transplant considerations in multiple myeloma.

Ajai Chari, MD, discusses important patient factors to consider when selecting between currently approved BCMA-targeted therapies for the treatment of patients with multiple myeloma.

Ajai Chari, MD, discusses the significance of the FDA approval of talquetamab in patients with relapsed/refractory multiple myeloma.

Ajai Chari, MD, discusses recommendations for minimal residual disease testing in patients with multiple myeloma.